drugset

drugset / Trial / NCT00639483

Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

NCT00639483 ↗

Phase 2 Completed 270 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy and safety of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia

Timeline

Start: 2003-03
Primary completion: —
Completion: 2004-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	200 mg	Oral

Indications